Neil Weir is a Venture Partner at SV and CEO of Sitryx Therapeutics, an SV portfolio company. He joined the SV Venture Partner Program in September 2020.
Sitryx is working in the field of immunometabolism to bring novel medicines to unmet needs in inflammation, autoimmunity and immuno-oncology.
Prior to Sitryx, Neil was Senior Vice-President, Discovery, at UCB S.A. a role in which he oversaw an integrated portfolio of small molecule and antibody projects in the fields of immunology, bone disease and neurology. Prior to UCB, Neil was Head of Research at Celltech, UK. Neil and his teams transitioned 33 novel biological and chemical entities into development in immunology, oncology, bone and neurology including the marketed medicines Cimzia, Besponsa and Romosozumab.
Neil was an inventor of Cimzia® and dual signalling domain chimeric receptors now known as second generation CAR-Ts. Neil served as chair of the board of Beryllium BioSciences in Boston prior to its acquisition by UCB and as a non-exec member of the boards of the RNA Medicines company (Boston) and Ondek (Perth WA). Neil chaired the UK ABPI innovation board from 2012 to 2018, has been involved in various MRC advisory board positions and was a member of the steering board for the German federal government’s Neuroallianz consortium.
BSc, Biological Sciences at the University of Edinburgh and PhD in microbial physiology from the University of Kent.